3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Breast Neoplasms
6
Neoplasm Metastasis
4
Colorectal Neoplasms
2
Pancreatic Neoplasms
1
Neoplasms
1
HER2-Positive Primary Breast Cancer
1
Gastrointestinal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Diseases
1
Adenocarcinoma
1
Interventions
Cetuximab
5
Bevacizumab
4
pembrolizumab
3
Leucovorin
3
Irinotecan
3
Fluorouracil
3
trifluridine tipiracil drug combination
2
trastuzumab deruxtecan
2
larotrectinib
2
encorafenib
2
binimetinib
2
Trastuzumab
2
Oxaliplatin
2
Nivolumab
2
HMPL-013
2
Afatinib
2
ulixertinib
1
tucatinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sotorasib
1
sapanisertib
1
relatlimab
1
regorafenib
1
pralsetinib
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
ipatasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
Colorectal Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT04482309
2026-04-09
DPT02
AstraZeneca
Phase 2
Active not recruiting
477 enrolled
1 FDA
NCT04744831
2026-01-14
DESTINY-CRC02
Daiichi Sankyo
Phase 2
Completed
122 enrolled
21 charts
1 FDA